Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026

Immutep (NASDAQ: IMMP) will present IMP761 Phase I study data at ACR Convergence on November 10, 2026, following late-breaking abstract acceptance.

Rhea-AI Summary

Immutep (NASDAQ: IMMP) will present IMP761 Phase I study data at ACR Convergence on November 10, 2026, following late-breaking abstract acceptance.

The poster covers a randomised, placebo-controlled, double-blind first-in-human study in healthy volunteers. IMP761 is an antibody designed to activate LAG-3, an immune-system receptor, to suppress immune responses. The study is being conducted by the Centre for Human Drug Research in Leiden, the Netherlands. Poster LB09 is scheduled for 10:30 AM–12:30 PM ET at the meeting in Orlando, Florida. First interim study data were presented at EULAR in June 2026. The poster will be available on Immutep’s website following the presentation.

Key Terms

lag-3, placebo-controlled, double-blind, keyhole limpet haemocyanin

4 terms

lag-3 medical

"first-in-class immunosuppressive LAG-3 agonist antibody"

A protein found on certain immune cells that acts like a brake, helping control how aggressively the immune system attacks threats such as cancer. Drugs that block or modify LAG-3 can release that brake, potentially enabling stronger anti‑cancer responses; because such treatments can change patient outcomes and open new markets, LAG-3-related data, approvals, or setbacks often have big effects on a biotech or pharmaceutical company’s valuation.

placebo-controlled medical

"randomised, placebo-controlled, double-blind first-in-human Phase I study"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

double-blind medical

"randomised, placebo-controlled, double-blind first-in-human Phase I study"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

keyhole limpet haemocyanin medical

"using CHDR’s keyhole limpet haemocyanin (KLH) challenge model"

A large oxygen-carrying protein from the marine mollusk known as the keyhole limpet, used in medicine and biotechnology as a highly immunogenic carrier. Because it is foreign and strongly stimulates the immune system, it is commonly chemically linked to small molecules or weak antigens (conjugation) to provoke a stronger antibody response for vaccines, antibody production, or diagnostic assays; it is not itself a specific antigen for the target but acts as a scaffold and immune stimulant. As a biologic material, batches can vary and its marine origin is relevant for manufacturing, regulatory handling, and potential allergic considerations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Late-breaking poster will present data from the first-in-human Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, in healthy volunteers

SYDNEY, AUSTRALIA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that a late-breaking abstract has been accepted for poster presentation at the American College of Rheumatology (ACR) Convergence 2026, taking place from 6 to 11 November 2026 in Orlando, Florida, USA.

The poster will present data from the randomised, placebo-controlled, double-blind first-in-human Phase I study (NCT06637865) of IMP761, Immutep’s first-in-class immunosuppressive LAG-3 agonist antibody. The study is being conducted by the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands, in healthy volunteers using CHDR’s keyhole limpet haemocyanin (KLH) challenge model. First interim data from the study were presented at the EULAR 2026 Congress in June 2026.

Details of the presentation are as follows:

Title	IMP761, a Novel Immunosuppressive Lymphocyte Activation Gene-3 (LAG-3) Agonist Antibody in the Clinic
Trial	IMP761-P001 (NCT06637865)
Session category	Late-Breaking Abstract Poster Session (LB01–LB18)
First Author	Christian Mueller, Chief Development Officer, Immutep
Presentation #	LB09
Date and time	Tuesday, November 10, 2026, 10:30 AM – 12:30 PM ET

The poster will be made available on the Posters & Publications page of Immutep’s website following the presentation.

About IMP761

IMP761 is a first-in-class immunosuppressive LAG-3 agonist antibody and the only LAG-3 agonist currently in clinical development. It is designed to selectively target activated T cells at sites of inflammation, with the aim of reducing pathological immune responses while preserving systemic immune function. Preclinical data supporting IMP761’s mechanism have been published in the Journal of Immunology,¹ with additional supporting data in oligoarticular juvenile idiopathic arthritis (o-JIA) published in Pediatric Research.² The program builds on Immutep’s expertise in the LAG-3 pathway and is being developed as a potential mechanism-based therapy across multiple autoimmune indications driven by T-cell-mediated inflammation.

About Immutep

Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of IMP761. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.

Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company’s ability to advance its product candidates.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.

Disclaimer

This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.

This announcement was authorised for release by the CEO of Immutep Limited.

Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

U.S. Investors/Media:
Matthew Beck, astr partners
+1 (917) 415 1750; matthew.beck@astrpartners.com

¹ Angin M, Brignone C, Triebel F. A LAG-3-Specific Agonist Antibody for the Treatment of T Cell-Induced Autoimmune Diseases. J Immunol. 2020;204:810-818.
² Sag E, Demir S, Aspari M, et al. Juvenile idiopathic arthritis: lymphocyte activation gene-3 is a central immune receptor in children with oligoarticular subtypes. Pediatr Res. 2021;90:744-751.